A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 7226 participants.
Also called NCT01042769
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 7,226 participants
- Sponsor
- Registry
-
NCT01042769
-
- Other papers using this trial's data
- Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome
- Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Australia, Brazil, Canada, China, Czechia, Denmark, France, Germany, Grenada, Hungary, India, Ireland, Italy, Malaysia, Mexico, Netherlands, New Zealand, Poland, Romania, Russia, South Korea, Spain, Sweden, Thailand, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01042769. Randomized; double masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2013-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
- Condition
- Diabetes Mellitus Type 2
- Intervention (Drug)
- Aleglitazar
- Intervention (Drug)
- Placebo
- Lead sponsor
- Hoffmann-La Roche
Record details
- Record id
cardio:ct-nct01042769- Content hash
3b06c9ff67c1543ed489f9e26172af8dc0f2d3706b033f14bd6b4db60d99b181